Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""ESOMEPRAZOLE"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 3304
Tytuł:
A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease.
Autorzy:
Park SH; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Lee KN; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Lee OY; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Choi MG; Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim JH; Department of Internal Medicine, Gangnam Severance Hospital, Seoul, Korea.
Sung IK; Department of Internal Medicine, Konkuk University College of Medicine, Seoul, Korea.
Jang JY; Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea.
Park KS; Department of Internal Medicine, Keimyung University College of Medicine, Daegu, Korea.
Chun HJ; Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
Kim EY; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee JK; Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.
Jang JS; Department of Internal Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea.
Kim GH; Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Hong SJ; Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
Lee YC; Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Choi SC; Department of Internal Medicine, Wonkwang University College of Medicine, Iksan, Korea.
Kim HS; Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
Kim TO; Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.
Baik GH; Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
Jeon YC; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2023 Mar 15; Vol. 17 (2), pp. 226-233. Date of Electronic Publication: 2022 Jun 22.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article
MeSH Terms:
Esomeprazole*/adverse effects
Gastroesophageal Reflux*/drug therapy
Gastroesophageal Reflux*/complications
Humans ; Heartburn/drug therapy ; Heartburn/etiology ; Sodium Bicarbonate ; Treatment Outcome ; Proton Pump Inhibitors ; Double-Blind Method
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study.
Autorzy:
Kim BW; Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Park JJ; Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
Moon HS; Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Lee WS; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Shim KN; Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Baik GH; Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
Lim YJ; Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.
Lee HL; Department of Internal Medicine, Hanyang University Medical Center, Seoul, Korea.
Youn YH; Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Park JC; Department of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Sung IK; Department of Internal Medicine, Konkuk University Medical Center, Konkuk University College of Medicine, Seoul, Korea.
Chung H; Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Moon JS; Department of Internal Medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
Kim GH; Department of Internal Medicine, Pusan National University College of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Hong SJ; Digestive Disease Center and Research Institute, Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
Choi HS; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2024 Mar 15; Vol. 18 (2), pp. 257-264. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Stomach Ulcer*/drug therapy
Stomach Ulcer*/surgery
Stomach Ulcer*/etiology
Stomach Neoplasms*/etiology
Endoscopic Mucosal Resection*/adverse effects
Benzene Derivatives*
Imidazoles*
Humans ; Esomeprazole/therapeutic use ; Ulcer/drug therapy ; Ulcer/etiology ; Proton Pump Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects.
Autorzy:
Hwang I; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Ji SC; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Oh J; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Kim H; Onconic Therapeutics Inc., Seoul, Republic of Korea.
Cha H; Onconic Therapeutics Inc., Seoul, Republic of Korea.
Kim J; Onconic Therapeutics Inc., Seoul, Republic of Korea.
Lee CS; Jeil Pharmaceutical CO., LTD., Seoul, Republic of Korea.
Yu KS; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Lee S; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Apr; Vol. 57 (7), pp. 763-772. Date of Electronic Publication: 2023 Feb 02.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Potassium*
Esomeprazole*
Humans ; Male ; Healthy Volunteers ; Double-Blind Method ; Gastrins ; Dose-Response Relationship, Drug ; Administration, Oral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetics of Esomeprazole Magnesium After Single Oral Doses in Healthy Subjects: Bioequivalence Study and Food Effects.
Autorzy:
Zhong XF; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Zhou G; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Xu SM; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Li XM; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Xu Y; Baiyang Pharmaceutical Limited by Share Ltd, Qingdao, PR China.
Liu WL; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Zhang YX; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
He LC; Anbisheng Pharmaceutical Limited by Share Ltd, Shanghai, PR China.
Shen QY; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Xu PS; Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Nov; Vol. 11 (11), pp. 1308-1313. Date of Electronic Publication: 2022 Jul 13.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Esomeprazole*/adverse effects
Adult ; Humans ; Therapeutic Equivalency ; Healthy Volunteers ; Area Under Curve ; Administration, Oral ; Cross-Over Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study.
Autorzy:
Lim H; Department of Internal Medicine, University of Hallym College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
Park JK; Division of Gastroenterology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Republic of Korea.
Chung H; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee SH; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.
Park JM; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Park JH; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine, Seoul, Republic of Korea.
Kim GH; Department of Internal Medicine, Biomedical Research Institute, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Republic of Korea.
Shin SK; Division of Gastroenterology, Institute of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hong SJ; Digestive Disease Center and Research Institute, Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
Lee KJ; Department of Gastroenterology, Ajou University School of Medicine, Suwon, Republic of Korea.
Park MI; Department of Internal Medicine, Kosin University College of Medicine, Busan, Republic of Korea.
Jung HK; Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Republic of Korea.
Kim HS; Department of internal medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.
Sung JK; Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
Jeon SW; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
Choi SC; Department of Gastroenterology, Digestive Disease Research Institute, Wonkwang University Hospital, Iksan, Republic of Korea.
Moon JS; Department of Internal Medicine, Inje University College of Medicine, Seoul, Republic of Korea.
Kim N; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Park JJ; Division of Gastroenterology, Department of Internal Medicine, Korea University College of Medicine, Guro Hospital, Seoul, Republic of Korea.
Hong SH; Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.
Kim NY; Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.
Jung HY; Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2023 Dec 18; Vol. 23 (1), pp. 447. Date of Electronic Publication: 2023 Dec 18.
Typ publikacji:
Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Esophagitis*
Esophagitis, Peptic*/drug therapy
Gastroesophageal Reflux*/drug therapy
Gastroesophageal Reflux*/diagnosis
Peptic Ulcer*
Humans ; Double-Blind Method ; Esomeprazole/adverse effects ; Proton Pump Inhibitors/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
Autorzy:
Tack J; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Vladimirov B; Department of Gastroenterology, University Hospital 'Queen Giovanna- ISUL', Medical University of Sofia, Sofia, Bulgaria.
Horny I; Department of Gastroenterology and Internal medicine, Strakonice Hospital, Czech Republic.
Chong CF; Currently Hoffmann-La Roche, Formerly Takeda Development Center Asia, Basel, Switzerland.
Eisner J; Formerly Takeda Pharmaceuticals International Co., Takeda Pharmaceuticals International Co., Cambridge, USA.
Czerniak R; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Takanami Y; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło:
Neurogastroenterology and motility [Neurogastroenterol Motil] 2023 Jan; Vol. 35 (1), pp. e14468. Date of Electronic Publication: 2022 Sep 30.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Esomeprazole*/therapeutic use
Gastroesophageal Reflux*/drug therapy
Gastroesophageal Reflux*/diagnosis
Humans ; Female ; Middle Aged ; Proton Pump Inhibitors/therapeutic use ; Treatment Outcome ; Double-Blind Method ; Heartburn/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Simultaneous separation of naproxen and 6-O-desmethylnaproxen metabolite in saliva samples by liquid chromatography-tandem mass spectrometry: Pharmacokinetic study of naproxen alone and associated with esomeprazol-Results.
Autorzy:
Oliveira GM; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Dionísio TJ; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Polanco NLDH; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Siqueira-Sandrin VS; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Faria FAC; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Santos CF; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Calvo AM; Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Dec 01; Vol. 17 (12), pp. e0278411. Date of Electronic Publication: 2022 Dec 01 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Esomeprazole*
Naproxen*
Humans ; Chromatography, Liquid ; Tandem Mass Spectrometry ; Saliva
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.
Autorzy:
Ebrahimpour A; Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Ahir M; Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Wang M; Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Jegga AG; Division of Biomedical Informatics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, 45229, USA.
Bonnen MD; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.
Eissa NT; Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, 92697, USA.
Montesi SB; Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA.
Raghu G; Division of Pulmonary and Critical Care Medicine, Center for Interstitial Lung Disease, University of Washington, Seattle, WA, 98195, USA.
Ghebre YT; Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. .; Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA. .; Department of Medicine, Section on Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. .; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Nov 30; Vol. 12 (1), pp. 20668. Date of Electronic Publication: 2022 Nov 30.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Esomeprazole*/pharmacology
Idiopathic Pulmonary Fibrosis*/drug therapy
Animals ; Mice ; Transforming Growth Factor beta ; Prospective Studies ; Retrospective Studies ; Proton Pump Inhibitors/pharmacology ; Disease Models, Animal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A population PK-PD model of YH4808, a novel P-CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808.
Autorzy:
Chung TK; Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.
Lee HA; Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Lee KR; Laboratory Animal Resource Center, Korea Research Institute of Bioscience and Biotechnology, Ochang, Chungbuk, South Korea.; Department of Bioscience, University of Science and Technology, Daejeon, South Korea.
Jang SB; Clinical Pharmacology Team, Clinical Development and Medical Department, Yuhan Corporation, Seoul, South Korea.
Yu KS; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.
Lee H; Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.; Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea.; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.; Center for Convergence Approaches in Drug Development, Seoul, South Korea.; Advanced Institutes of Convergence Technology, Suwon, South Korea.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Sep; Vol. 11 (9), pp. 1223-1233. Date of Electronic Publication: 2022 Jul 09.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Ulcer Agents*
Esomeprazole*/analogs & derivatives
Esomeprazole*/pharmacokinetics
Feedback ; Humans ; Hydrogen-Ion Concentration ; Male
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
An extended 36-week oral esomeprazole improved long-term recurrent peptic ulcer bleeding in patients at high risk of rebleeding.
Autorzy:
Chiang HC; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.
Yang EH; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.
Hu HM; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100, Ziyou 1st Rd, Kaohsiung, 807377, Taiwan.; Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, 68, Zhonghua 3rd Rd, Kaohsiung, 801735, Taiwan.
Chen WY; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.; Department of Public Health, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.
Chang WL; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, North Dist, Tainan, 704302, Taiwan.
Wu CT; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, North Dist, Tainan, 704302, Taiwan.
Wu DC; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100, Ziyou 1st Rd, Kaohsiung, 807377, Taiwan.; School of Medicine, College of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100, Ziyou 1st Rd, Kaohsiung, 807377, Taiwan.
Sheu BS; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan.; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, North Dist, Tainan, 704302, Taiwan.
Cheng HC; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng Li Rd, Tainan, 704302, Taiwan. .; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, North Dist, Tainan, 704302, Taiwan. .; Institute of Molecular Medicine, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, North Dist, Tainan, 704302, Taiwan. .; Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, 125 Jhongshan Road, West Central Dist, Tainan, 700007, Taiwan. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2022 Oct 21; Vol. 22 (1), pp. 439. Date of Electronic Publication: 2022 Oct 21.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Esomeprazole*/therapeutic use
Peptic Ulcer*/complications
Peptic Ulcer*/drug therapy
Humans ; Proton Pump Inhibitors/therapeutic use ; Ulcer/complications ; Peptic Ulcer Hemorrhage/drug therapy ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Application of Different UV Spectrophotometric Methods for Quantitative Analysis of Acotiamide and Esomeprazole.
Autorzy:
Abdelazim AH; Al-Azhar University, Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, 11751 Nasr City, Cairo, Egypt.
Ramzy S; Al-Azhar University, Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, 11751 Nasr City, Cairo, Egypt.
Shahin M; Damanhour University, Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Beheira, Egypt.
Pokaż więcej
Źródło:
Journal of AOAC International [J AOAC Int] 2022 Sep 06; Vol. 105 (5), pp. 1475-1478.
Typ publikacji:
Journal Article
MeSH Terms:
Esomeprazole*
Thiazoles*
Benzamides ; Spectrophotometry/methods ; Tablets
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.
Autorzy:
Kaur Mukker J; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Dukes G; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Wang L; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Huh S; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Khudyakov P; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Nishihara M; Takeda Pharmaceutical Company, Ltd., Fujisawa, Kanagawa, Japan.
Chen C; Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2022 May; Vol. 15 (5), pp. 1281-1290. Date of Electronic Publication: 2022 Feb 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Esomeprazole*/adverse effects
Esomeprazole*/pharmacokinetics
Proton Pump Inhibitors*/adverse effects
Adult ; Cross-Over Studies ; Drug Interactions ; Humans ; Pharmaceutical Preparations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Administering esomeprazole subcutaneously via a syringe driver in the palliative demographic: A case series.
Autorzy:
Hindmarsh J; Specialist Centre for Palliative Care, St. Benedict's Hospice, Sunderland, UK.; Department of Pharmacy, Sunderland Royal Hospital, Sunderland, UK.
Adelaja M; Department of Pharmacy, Sunderland Royal Hospital, Sunderland, UK.
Abd Latif S; Specialist Centre for Palliative Care, St. Benedict's Hospice, Sunderland, UK.
Lee M; Specialist Centre for Palliative Care, St. Benedict's Hospice, Sunderland, UK.
Pickard J; Specialist Centre for Palliative Care, St. Benedict's Hospice, Sunderland, UK.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 May; Vol. 47 (5), pp. 694-698. Date of Electronic Publication: 2021 Dec 27.
Typ publikacji:
Case Reports
MeSH Terms:
Esomeprazole*/adverse effects
Proton Pump Inhibitors*
Demography ; Gastrointestinal Hemorrhage/chemically induced ; Humans ; Palliative Care ; Syringes ; Treatment Outcome
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium.
Autorzy:
Boinpally R; AbbVie, Madison, New Jersey, USA.
Lu K; AbbVie, Madison, New Jersey, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Feb; Vol. 11 (2), pp. 270-277. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Esomeprazole*/administration & dosage
Esomeprazole*/adverse effects
Esomeprazole*/pharmacokinetics
Migraine Disorders*/drug therapy
Adult ; Female ; Humans ; Male ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyridines/pharmacokinetics ; Pyrroles/administration & dosage ; Pyrroles/adverse effects ; Pyrroles/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development, In-Vitro Characterization and Preclinical Evaluation of Esomeprazole-Encapsulated Proniosomal Formulation for the Enhancement of Anti-Ulcer Activity.
Autorzy:
Mohanty D; Department of Pharmaceutics, Anurag University, Hyderabad 500088, India.
Zafar A; Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka 72341, Saudi Arabia.
Jafar M; Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia.
Upadhyay AK; Department of Biotechnology, Thapar Institute of Engineering & Technology, Patila 147001, India.
Haque MA; Department of Pharmaceutical Analysis, Anurag University, Hyderabad 500088, India.
Gupta JK; Institute of Pharmaceutical Research, GLA University, Mathura 281406, India.
Bakshi V; Department of Pharmaceutics, Anurag University, Hyderabad 500088, India.
Ghoneim MM; Department of Pharmacy Practice, College of Pharmacy, Al-Maarefa University, Ad Diriyah 13713, Saudi Arabia.
Alshehri S; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Jahangir MA; Department of Pharmaceutics, Nibha Institute of Pharmaceutical Sciences, Rajgir 803116, India.
Ansari MJ; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, AlKharj 11942, Saudi Arabia.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2022 Apr 25; Vol. 27 (9). Date of Electronic Publication: 2022 Apr 25.
Typ publikacji:
Journal Article
MeSH Terms:
Esomeprazole*/pharmacology
Ulcer*
Administration, Cutaneous ; Biological Availability ; Drug Carriers ; Drug Liberation ; Humans ; Particle Size
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
Autorzy:
Ramste M; Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Ritvos M; Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Häyrynen S; Veracell Oy, Tampere, Finland.
Kiiski JI; Department of Clinical Pharmacology and Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Niemi M; Department of Clinical Pharmacology and Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
Sinisalo J; Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Pokaż więcej
Źródło:
Clinical and translational science [Clin Transl Sci] 2023 Oct; Vol. 16 (10), pp. 2010-2020. Date of Electronic Publication: 2023 Aug 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Platelet Aggregation Inhibitors*/adverse effects
Stroke*
Humans ; Clopidogrel/adverse effects ; Alleles ; Esomeprazole/adverse effects ; Omeprazole/adverse effects ; Cytochrome P-450 CYP2C19/genetics ; Prospective Studies ; Genotype ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Multivariate Model Update Chemometric Methods for Determination of Prednisolone and Esomeprazole in Spiked Human Plasma: A Comparative Study.
Autorzy:
Farid NF; Beni-Suef University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Alshaheed Shehata Ahmad Hegazy St, 62514 Beni-Suef, Egypt.
Magdy MA; Beni-Suef University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Alshaheed Shehata Ahmad Hegazy St, 62514 Beni-Suef, Egypt.
Anwar BH; Beni-Suef University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Alshaheed Shehata Ahmad Hegazy St, 62514 Beni-Suef, Egypt.
Abdelhamid NS; Beni-Suef University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Alshaheed Shehata Ahmad Hegazy St, 62514 Beni-Suef, Egypt.
Pokaż więcej
Źródło:
Journal of AOAC International [J AOAC Int] 2022 Feb 04; Vol. 105 (1), pp. 317-322.
Typ publikacji:
Journal Article
MeSH Terms:
Esomeprazole*
Pharmaceutical Preparations*
Chemometrics ; Humans ; Least-Squares Analysis ; Prednisolone ; Spectrophotometry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Recent Analytical Methodologies for the Determination of Omeprazole and/or Its Active Isomer Esomeprazole in Different Matrices: A Critical Review.
Autorzy:
El-Kimary EI; Faculty of Pharmacy, Department of Pharmaceutical Analytical Chemistry, University of Alexandria, El-Messalah, Alexandria, Egypt.
Ragab MAA; Faculty of Pharmacy, Department of Pharmaceutical Analytical Chemistry, University of Alexandria, El-Messalah, Alexandria, Egypt.
Pokaż więcej
Źródło:
Critical reviews in analytical chemistry [Crit Rev Anal Chem] 2022; Vol. 52 (1), pp. 106-130. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Esomeprazole*
Omeprazole*
Electrochemical Techniques ; Isomerism ; Stereoisomerism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.
Autorzy:
Xu H; Pfizer Inc., La Jolla, California, USA.
O'Gorman M; Pfizer Inc., Groton, Connecticut, USA.
Matschke K; Pfizer Inc., Collegeville, Pennsylvania, USA.
Boutros T; Pfizer Inc., La Jolla, California, USA.
Brega N; Pfizer Inc., Milan, Italy.
Tan W; Pfizer Inc., La Jolla, California, USA.
Bello A; Pfizer Inc., New York, New York, USA.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Jan; Vol. 11 (1), pp. 34-42. Date of Electronic Publication: 2021 Nov 26.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Esomeprazole*/adverse effects
Proton Pump Inhibitors*/adverse effects
Adult ; Crizotinib/adverse effects ; Cross-Over Studies ; Healthy Volunteers ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 3304

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies